Neutropenia associated with rituximab therapy

Current Opinion in Hematology

Volumn 18, Issue 1, 2011, Pages 49-54

  Grant, Cliona ^a   Wilson, Wyndham H ^a   Dunleavy, Kieron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

B cell recovery; Lymphoma; Neutropenia; Rituximab; SDF 1

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; GRANULOCYTE ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; VINCRISTINE;

ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; DISEASE ASSOCIATION; GRANULOCYTE; HOMEOSTASIS; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; LARGE GRANULAR LYMPHOCYTE; LATE ONSET NEUTROPENIA; MANTLE CELL LYMPHOMA; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CHEMOKINE CXCL12; GRANULOCYTES; HOMEOSTASIS; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; NEUTROPENIA;

EID: 79851509273     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283414edf     Document Type: Article

References (34)

1. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125:1678-1685. (Pubitemid 10018582)
2. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:3266-3274. (Pubitemid 27419340)
3. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti- CD20 monoclonal antibody therapy in patients with relapsed low-grade non- Hodgkin's lymphoma. Blood 1997; 90:2188-2195. (Pubitemid 27392702)
4. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000; 18:3135-3143.
5. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and postgerminal center biomarkers. J Clin Oncol 2008; 26:2717-2724.
6. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:2165-2170. (Pubitemid 32366970)
7. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol 2010; 47:180-186.
8. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152.
9. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833. (Pubitemid 28363048)
10. Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005; 106:795-802. (Pubitemid 41076417)
11. Papadaki T, Stamatopoulos K, Stavroyianni N, et al. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002; 26:597-600. (Pubitemid 34462174)
12. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348:2691-2694; discussion 2694.
13. Nitta E, Izutsu K, Sato T, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapyas a primary treatment of CD20- positive B-cell lymphoma: a single-institution study. Ann Oncol 2007; 18:364-369. (Pubitemid 46323107)
14. Lai GG, Lim ST, Tao M, et al. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol 2009; 84:414-417.
15. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33:921-923. (Pubitemid 38660125)
16. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47:1013-1017. (Pubitemid 44102962)
17. Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121:913-918. (Pubitemid 36760311)
18. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, et al. Lateonset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007; 157:1271-1273. (Pubitemid 350119793)
19. Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood 2003; 102:1557-1558.
20. Suratt BT, Petty JM, Young SK, et al. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood 2004; 104:565-571. (Pubitemid 38900043)
21. Martin C, Burdon PC, Bridger G, et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003; 19:583-593. (Pubitemid 37311439)
22. Tokoyoda K, Egawa T, Sugiyama T, et al. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004; 20:707-718. (Pubitemid 38757441)
23. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30:973-981. (Pubitemid 35286613)
24. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10:463-471. (Pubitemid 29205482)
25. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393:595-599. (Pubitemid 28319251)
26. Egawa T, Kawabata K, Kawamoto H, et al. The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity 2001; 15:323-334. (Pubitemid 32816880)
27. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10:858-864. (Pubitemid 39070860)
28. Villalba S, Salvucci O, Aoki Y, et al. Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. J Leukoc Biol 2003; 74:880-888. (Pubitemid 38040364)
29. Sei S, O'Neill DP, Stewart SK, et al. Increased level of stromal cell-derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma. Cancer Res 2001; 61:5028-5037. (Pubitemid 32681531)
30. Forster R, Kremmer E, Schubel A, et al. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol 1998; 160:1522-1531. (Pubitemid 28093457)
31. Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist 2004; 9:247-258. (Pubitemid 38756874)
32. Wong KF, Chan JC, Liu HS, et al. Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia: report of two cases and review of the literature. Br J Haematol 2002; 116:598-600. (Pubitemid 34178659)
33. Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF- induced B-cell recovery. Haematologica 2007; 92:e20-e23.
34. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:279-284.